RadxTools for assessing tumor treatment response on imaging
RadxTools for assessing tumor treatment response on imaging
批准号:
10593646
负责人:
Pallavi Tiwari
金额:
$23.4万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2023-06-30
关键词:
3-DimensionalAdjuvantAdultAffectAwardBiophysicsBrain NeoplasmsCellsCharacteristicsChildChildhood Brain NeoplasmChildhood MedulloblastomasClinicalClinical stratificationCommunitiesDataDescriptorDevelopmentDoseEntropyEtiologyExcisionFoundationsFutureGoalsHeterogeneityHistologyImageInformaticsMRI ScansMagnetic Resonance ImagingMalignant - descriptorMalignant Childhood NeoplasmMetastatic Neoplasm to the LeptomeningesModelingMolecularMorbidity - disease rateOperative Surgical ProceduresOutcomePatientsPediatric HospitalsPediatric cohortPrognosisQuality of lifeRadxToolsResidual TumorsRiskShapesStratificationSubgroupSurvival RateTechnologyTextureTreatment ProtocolsUnited States National Institutes of HealthVasodilationWorkanticancer researchbasebrain parenchymachemotherapyclinical careclinical riskhigh riskimprovedindexingirradiationlong-term sequelaemedulloblastomaprognosticationradiomicsrisk stratificationtooltreatment responsetreatment strategytumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT: Medulloblastoma (MB) is a malignant, fast-growing pediatric brain tumor with heterogenous
outcomes and a 5-year survival rate of 70-80%. Current treatment strategies for MB patients include surgical
resection, chemotherapy, and craniospinal irradiation (CSI), with dose-intensification in high-risk patients
(defined as residual tumor >1.5 cm2, evidence of leptomeningeal metastases, or large-cell/anaplastic histology)
to improve clinical outcomes, while de-escalation of therapy to reduce long-term sequelae in standard-risk MB
patients. Unfortunately, this treatment protocol has only proven useful as a rough guide for predicting
prognosis with the existing clinical stratification; particularly, the 5-year survival rate for the high-risk patients
are currently at about 60%. Additionally, the existing clinical risk stratification fails to identify about 20–30% of
standard-risk patients who might be overtreated and eventually suffer from long-term morbidities that
significantly affect their quality of life. Consequently, there is a critical need for reliable tools to risk-stratify MB
patients based on their survival, with the goal of identifying high-risk MB cases who are most likely to receive
added benefit from adjuvant and concomitant therapy, while de-escalating therapy in low/standard-risk cases.
Through an ongoing NCI U01 award (1U01CA248226-01) from the Informatics Technology for Cancer
Research (ITCR), our group has been leading the development of peri-tumoral (Eur. Rad 20172, AJNR 20183)
and intra-tumoral spatial heterogeneity radiomics, that go beyond texture, shape-based approaches, for
characterization of adult tumors. As an extension to our U01 efforts, in this supplemental project, we propose
to develop two informatics modules for (1) radiomic analysis for tumor characterization on clinical MRI scans
(Gd-T1w, T2w, FLAIR), and (2) a risk-stratification module, for survival risk-stratification of pediatric MB patients.
In our preliminary work, we demonstrated that our biophysical deformation descriptor that characterizes subtle
changes in vasodilation from brain parenchyma on Gd-T1w MRI scans, had higher concordance-index (C-
index) in predicting overall survival in MB patients compared to employing the molecular subgroup-based
stratification [n=89, p<0.05 vs. p=0.6, C-index=0.831 vs. 0.80]. The 2 modules developed in our supplement
project will be leveraged to improve on our initial model (using deformations alone), to (a) include features
relating to (1) 3D topology, (2) localized entropy, and (3) peri-tumoral features from the vicinity of the tumor and
(b) perform MRI-based risk-stratification of MB patients based on their survival characteristics, independent of
molecular stratification. Our collaborative efforts with Children's Hospital Cinncinati, Nationawide Childrens
Columbus, and Children's Brain Tumor Network, will led to creation of a rich, one-of-the-largest MB cohorts for
the pediatric cancer community and will serve as the foundation of ongoing and future studies focused on
resolving MB aetiology. Following successful completion, we will make the multi-institutional studies and the
associated mRRisc features publicly available by leveraging ongoing efforts through ITCR.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1093/noajnl/vdaa148
发表时间:
2020-12
期刊:
Neuro-oncology advances
影响因子:
--
作者:
[Beig N, Bera K, Tiwari P]
通讯作者:
Tiwari P
DOI:
10.3389/fncom.2020.563439
发表时间:
2020
期刊:
Frontiers in computational neuroscience
影响因子:
3.2
作者:
[Ismail M, Hill V, Statsevych V, Mason E, Correa R, Prasanna P, Singh G, Bera K, Thawani R, Ahluwalia M, Madabhushi A, Tiwari P]
通讯作者:
Tiwari P
DOI:
10.3390/cancers12123663
发表时间:
2020-12-07
期刊:
Cancers
影响因子:
5.2
作者:
[Alvarez-Jimenez C, Sandino AA, Prasanna P, Gupta A, Viswanath SE, Romero E]
通讯作者:
Romero E
Opportunities and Advances in Radiomics and Radiogenomics for Pediatric Medulloblastoma Tumors.
小儿髓母细胞瘤肿瘤的放射组学和放射基因组学的机会和进步。
DOI:
10.3390/diagnostics13172727
发表时间:
2023-08-22
期刊:
DIAGNOSTICS
影响因子:
3.6
作者:
[Ismail, Marwa, Craig, Stephen, Ahmed, Raheel, de Blank, Peter, Tiwari, Pallavi]
通讯作者:
Tiwari, Pallavi
DOI:
10.3389/fmed.2023.1149056
发表时间:
2023
期刊:
Frontiers in medicine
影响因子:
3.9
作者:
[]
通讯作者:
Artificial Intelligence-based decision support for chemotherapy-response assessment in Brain Tumors
-
批准号:10589512
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:Pallavi Tiwari
-
依托单位:
RadxTools for assessing tumor treatment response on imaging
-
批准号:10477947
-
项目类别:
-
资助金额:$36.57万
-
财政年份:2020
-
负责人:Pallavi Tiwari
-
依托单位:
RadxTools for assessing tumor treatment response on imaging
-
批准号:10206077
-
项目类别:
-
资助金额:$38.3万
-
财政年份:2020
-
负责人:Pallavi Tiwari
-
依托单位:
海外基金